Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2

Carrie S Tambo1, Sarvind Tripathi1, B Gayani K Perera2

  • 1Department of Chemistry and Biochemistry, University of California, Santa Cruz, California 95064, United States.

ACS Chemical Biology
|February 1, 2023
PubMed

Insights

New research reveals how Cdk2 inhibitors affect cyclin binding. Type I inhibitors strengthen Cdk2-Cyclin A bonds by slowing dissociation, while Type II inhibitors weaken them, impacting cancer drug development.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cyclin-dependent kinases (CDKs) are crucial for cell proliferation and are targets in cancer drug discovery.
  • Understanding CDK-cyclin interactions is vital for cancer therapy, but specificity remains unclear.
  • CDK-cyclin binding kinetics influence cell cycle regulation and drug efficacy.

Purpose of the Study:

  • To develop a biolayer interferometry assay for quantifying CDK-cyclin binding.
  • To investigate the impact of Cdk2 inhibitors on Cyclin A (CycA) binding kinetics.
  • To elucidate the molecular mechanisms behind CDK-cyclin specificity and drug interactions.

Main Methods:

  • Developed a biolayer interferometry assay to measure CDK-cyclin binding kinetics.
  • Quantified association and dissociation rates of Cdk2 with Cyclin A (CycA).
  • Assessed the effects of Type I and Type II Cdk2 inhibitors on CycA binding.

Main Results:

  • Type I Cdk2 inhibitors increased Cdk2-CycA affinity by slowing cyclin dissociation.
  • Type II inhibitors and other small molecules decreased affinity through altered association/dissociation kinetics.
  • Differential effects of inhibitors suggest Cdk2 active site plasticity influences cyclin binding.

Conclusions:

  • The developed assay facilitates CDK-cyclin interaction analysis.
  • Cdk2 inhibitor mechanisms vary, impacting cyclin binding kinetics differently.
  • CDK active site dynamics are key to understanding drug interactions and developing targeted cancer therapies.

Related Concept Videos